Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 177.50
Bid: 170.00
Ask: 185.00
Change: -2.50 (-1.39%)
Spread: 15.00 (8.824%)
Open: 180.00
High: 182.50
Low: 177.50
Prev. Close: 180.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

Thu, 13th Sep 2018 10:49

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank of Scotland, up 1.5%. The state-backed lender could use up to GBP4 billion of extra capital to pay out a special dividends to shareholders, The Times newspaper reported. RBS Chairman Howard Davies told the newspaper that, despite wanting to use the spare cash to buy the bank's shares from the government, if shareholders wanted the special dividend it was a possible option. The special dividend could be up to 33 pence per share to investors, who have not received a payout from the bank in more than 10 years, the newspaper reported. "If there are a lot of shareholders pressing for a special dividend, that is something we would consider," Davies told the Times. ----------Antofagasta, up 0.9%. HSBC raised the Chilean copper miner to Hold from Reduce. ----------FTSE 100 - LOSERS----------Marks & Spencer Group, down 2.7%. Shares in the food, clothing and homewares retailer were lower after department store chain John Lewis Partnership issued a warning for the full-year, amid "challenging times in retail". For the six months to July 28, John Lewis Partnership, which also owns the Waitrose supermarket chain, reported 81% drop in pretax profit to GBP6.0 million from GBP30.8 million a year before. On an adjusted basis, pretax profit slumped 99% to GBP1.2 million. At the end of June, the company had said it expected its interim profit to be "near zero". Looking ahead, John Lewis said that it continues to expect full-year profits to "be substantially lower than last year for the group as a whole". "John Lewis is the bellwether of the UK retail sector, so the fact it's finding life so hard is an indication of just how dire things are on the high street right now," said Hargreaves Lansdown analyst Laith Khalaf. Rival chain Debenhams was down 11%. ----------FTSE 250 - WINNERS----------Grainger, up 5.3%. The residential landlord was raised to Buy from Add by Numis. ----------KAZ Minerals, up 1.8%. HSBC upgraded the Kazakhstan-based miner to Buy from Hold. ----------FTSE 250 - LOSERS----------Inmarsat, down 2.0%, Equiniti Group, down 1.8%. The stocks went ex-dividend meaning new buyers no longer qualify for the latest dividend payout. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Bushveld Minerals, up 18%. The miner said it has raised its interest in the Vametco vanadium mine located near Pretoria, South Africa, to 75% from 59.1%. Bushveld has acquired the entire 21.22% interest that Sojitz Noble Alloys Corp held in Strategic Minerals Corp, the 75% owner of Vametco, for USD20 million in cash. Following completion of the deal, Bushveld via its Bushveld Vametco unit will own 100% of Strategic Minerals Corp and therefore have an indirect beneficial interest of 75% in the Vametco mine. The company used its existing cash resources to complete the stake acquisition.----------OTHER MAIN MARKET AND AIM - LOSERS----------Faron Pharmaceuticals, down 15%. The biopharmaceutical company said its loss for the first half of its financial year increased on higher research costs. For the six months to June 30, the firm posted pretax loss of EUR14.1 million compared to EUR7.1 million a year prior on increased research & development costs by 95% year-on-year to EUR11.7 million from EUR6.0 million. Administrative expenses also increased to EUR2.4 million from EUR1.5 million. As the company focuses on developing drugs, it only generated revenue of EUR20,000 from product sales to Maruishi Pharmaceutical. A year ago revenue was nil. Research expenses increased as a result of clinical costs associated with an unsuccessful trial of Traumakine, a treatment for acute respiratory distress syndrome, as well as an increase in development activities for Clevegen, a potential treatment for various types of cancer, the company explained.----------
More News
11 Jun 2020 13:51

Faron receives EIC grant for 'MATINS' study

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has been selected to receive a €2.5m (£2.24m) grant from the European Innovation Council's 'Accelerator' pilot scheme, it announced on Thursday, to progress the 'MATINS' study, and related business activities.

Read more
11 Jun 2020 13:23

UK TRADING UPDATE SUMMARY: Churchill China Sales Hit By Virus

UK TRADING UPDATE SUMMARY: Churchill China Sales Hit By Virus

Read more
20 May 2020 10:37

Faron Pharmaceuticals confirms publication of 'crucial' study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that the results of its detailed analyses into the effects of glucocorticoids on intravenous interferon beta-1a activity, which arose following the 'INTEREST' trial in 2018, had been published in critical care journal Intensive Care Medicine.

Read more
11 May 2020 16:48

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Read more
11 May 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
5 May 2020 12:05

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Read more
5 May 2020 09:20

Faron Pharmaceuticals inks manufacturing deal with AGC Biologics

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has selected contract development and manufacturing organisation AGC Biologics as the commercial-scale manufacturer of 'Clevegen', it announced on Tuesday.

Read more
27 Apr 2020 13:52

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

Read more
27 Apr 2020 13:51

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

Read more
22 Apr 2020 18:42

Faron Raises EUR14 Million In Oversubscribed Share Placing

Faron Raises EUR14 Million In Oversubscribed Share Placing

Read more
21 Apr 2020 18:21

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Read more
1 Apr 2020 17:56

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

Read more
20 Mar 2020 11:25

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Read more
20 Mar 2020 10:49

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

Read more
13 Mar 2020 16:04

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.